Article Listing - MILES FILES SUPPLEMENTAL NDA
NEW YORK MEETINGS
10 February 1992
Two industry-related meetings are due to be held soon at the Loews Summit Hotel, New York: Cost Containment and Quality...
NEW FORMULATION OF JANSSEN'S NIZORAL
10 February 1992
Janssen Pharmaceutical has launched a new unperfumed, less viscous formulation of its Nizoral (ketoconazole) shampoo in the UK. Nizoral, Janssen...
FEMALE CONDOM RECOMMENDED FOR USA
10 February 1992
The Obstetrics and Gynec-ology Devices Advisory Commit-tee of the US Food and Drug Administration has recommended approval of Chartex Inter-national's...
SPAIN LOOKING TO GENERICS
10 February 1992
The full incorporation of Spain into the European Community, which takes effect on October 7, means that the country will...
EC "BLOW" TO NEW OTC PRODUCTS
10 February 1992
As it now stands, the Commission of the European Communities' proposed directive on advertising of over-the counter products in the...
INDUSTRY RESPONSE TO JAPAN DRUG PRICE MOVES
10 February 1992
The Koseisho, Japan's Ministry of Health and Welfare, is in the process of clarifying how it intends to implement the...
"KEY" US PATENT FOR BIOPURE'S HEMOPURE
10 February 1992
Boston, Massachusetts-based start-up company Biopure Corp reports that it has received a US patent covering its novel blood substitute Hemopure,...
GOOD YEAR FOR SANOFI IN 1991
10 February 1992
In 1991 sales at the French health and beauty concern, Elf Sanofi, increased 5.8% to 19.6 billion French francs ($3.6...
PFIZER PLANS NEW UNIT IN USA
10 February 1992
US pharmaceutical concern Pfizer is setting up a new unit at its Groton plant in the USA.The company has...
END OF FRENCH BLOC ON NEW DRUG INTROS
3 February 1992
The French government has agreed to renew the commission which gives advice to the Health Minister on drug-price fixing for...
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
